ChemoTech has signed a distributor agreement for its Human Care division with Gamma Gurus, which is currently a distributor for Vetiqure AB, ChemoTech's subsidiary for Animal Care. As communicated on the 18th of October 2023, Gamma Gurus and ChemoTech have been having discussions regarding an expansion of the cooperation to include the IQwave device for Tumour Specific Electroporation (TSE) to the human care market in Australia. On August 30, 2023, this agreement has been signed by both parties.

With cancer emerging as the leading cause of death in Australia, the country is actively investing in advanced research and treatments for diverse cancer types. The country's robust healthcare infrastructure, well-regulated clinical trials, and patient-centric approach contribute to its forefront position in delivering comprehensive and innovative cancer care. TSE holds substantial potential for personalized treatment of both superficial and deep solid tumours, particularly when integrated with chemotherapy, immunotherapy, and radiotherapy.